Search

everythinglearnresearchcommunity

for

Search:↓

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Hair loss discussion involves minoxidil, finasteride, and RU58841. Minoxidil non-responders may see results after adding stemoxydine due to increased enzyme presence.

Hair transplant success largely depends on individual biology, with many patients needing multiple procedures to achieve satisfactory density. Even top surgeons can't guarantee results, and many people use additional treatments like Minoxidil and Finasteride.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Mixing RU58841 with minoxidil compounded with tretinoin is discussed, with concerns about systemic absorption. Topical dutasteride and finasteride are also mentioned as treatments, with varying personal experiences and concerns about side effects.

The user believes that combining alfatrodial and fluridil with minoxidil effectively maintains hair, based on their 7-year experience. They suggest this combination for those who can't tolerate finasteride.

A 22-year-old with 4c hair is considering a hair transplant to address traction alopecia caused by braid extensions. They have tried derma stamping, oils, and minoxidil but stopped due to side effects.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

ShaneMorcs shared updated hair comparison photos and believes he's made progress. People commented on his improvement, asked about potential side effects, and inquired about the treatments he's using.

RU58841 from Vantanex is discussed for hair loss treatment. Users share experiences and question its legitimacy.

A user's progress with hair loss treatments over the past two years, including finasteride, minoxodil and dermarolling. Replies included speculations about whether or not this was the result of a hair transplant. The user confirmed that it was just meds.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

A user shared their hair regrowth journey from Norwood 7 at age 22 using oral minoxidil 10mg, dutasteride 0.5mg, and RU58841 70mg, along with a recent hair transplant. They experienced significant progress and discussed potential side effects, particularly with oral minoxidil, and plan to update on further growth.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.

A user shared their 5-month hair transplant progress, having undergone a procedure with 4100 grafts at MedBlue in Istanbul for $3,600. They started taking oral minoxidil and finasteride daily after the transplant and use topical minoxidil with microneedling every two weeks, reporting positive results and no unwanted hair growth.

The conversation discusses avoiding caffeine after Platelet-Rich Plasma (PRP) treatment for hair loss because caffeine is a vasoconstrictor, which can reduce blood flow and hinder the healing process that PRP aims to promote.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

A 24-year-old male saw major hair regrowth progress in 3 months using Nizoral, minoxidil, finasteride, vitamins, and dermarolling. After 7 months, he switched to liquid minoxidil, oral finasteride, and stopped dermarolling.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

A 19-year-old female with Diffuse Alopecia was advised by a dermatologist to use vitamin supplements, a hair serum, and antifungal drops, leading to some improvement. Other users suggested treatments like minoxidil, microneedling, and consulting a different dermatologist for further advice.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.